142: Ivermectin Explained - The Science Behind the Controversy with Dr. Ben Bikman

Bikman noted that as of late 2025, Tennessee, Arkansas, Idaho, Louisiana, and Texas have enacted OTC legislation, with more states considering similar bills. He compared this to the ease of buying ibuprofen, suggesting a legislative acknowledgment of the drug’s safety. He emphasized that this does not eliminate the need for medical supervision but counters the narrative that the drug is intrinsically dangerous. He views the legislative trend as evidence that ivermectin’s risk-benefit profile is being reassessed at the state level, independent of the federal-level controversy. For listeners who want to act on the information, the first practical step is to know the law in their state, then have an informed conversation with a clinician.

Bikman ended the lecture by reminding the audience he is not a clinician and that his goal is to equip listeners to have better conversations with their healthcare providers. He emphasized that the science of ivermectin deserves more credit than it has been given, and that understanding the molecular pathways — how complex I inhibition leads to AMPK activation, mTOR suppression, NF-κB blockade, and FXR-mediated insulin sensitization — allows a patient to ask more informed questions. He lamented that political controversy has created barriers to clinical research, but expressed hope that state-level funding and private clinical initiatives will generate the human data needed. He concluded by saying, ‘the data as they are now provide a very compelling mechanistic rationale for much greater clinical investigation.’

Bikman spent a significant portion of the lecture building the case that ivermectin recapitulates metformin’s core metabolic actions. He walked through how complex I inhibition reduces ATP, flips the AMP-to-ATP ratio, activates AMPK, and then AMPK simultaneously suppresses mTOR (reducing proliferation) and NF-κB (reducing inflammation). He then layered on ivermectin’s ability to bind the farnesoid X receptor (FXR), a nuclear hormone receptor that regulates glucose homeostasis and insulin sensitivity, an effect previously ascribed mainly to bile acid signaling. Preclinical diet-induced obesity models showed that ivermectin prevented the rise in fasting glucose, improved glucose tolerance, lowered blood pressure, and improved liver enzymes. Rodent work in a metabolic-syndrome model led the study authors to conclude that ivermectin ‘could be a promising candidate for combating metabolic syndrome.’ Bikman then highlighted a recent human pilot report of four type 2 diabetics whose HbA1c improved over months to two years on daily ivermectin, underscoring safety. He tempered optimism by emphasizing that no large-scale human trials exist, but argued the mechanistic coherence across FXR activation, AMPK signaling, anti-inflammatory action, and anti-adipogenic signals makes the question genuinely worth pursuing in controlled human studies.

Bikman detailed how ivermectin produces a dose-dependent reduction in basal oxygen consumption and maximal respiratory capacity in glioblastoma cells — the same metrics his own lab uses to measure mitochondrial function. It collapses the mitochondrial membrane potential, the electrochemical gradient necessary for ATP synthesis, and simultaneously raises reactive oxygen species and mitochondrial superoxide. This creates a state of profound mitochondrial dysfunction that cancer cells, with their high metabolic demand, cannot tolerate. Studies comparing leukemia cells to normal bone marrow cells, and renal cancer cells to normal kidney cells, found that cancerous cells were substantially more sensitive. Additionally, ivermectin promotes the degradation of PAK1, a kinase overactivated in most human cancers, without affecting non-tumorigenic breast cells. In pancreatic cancer, combining ivermectin with gemcitabine produced significantly greater apoptosis than gemcitabine alone, suppressing tumor growth in vivo. The mitochondrial story, coupled with PAK1 selectivity, provides a coherent rationale for ivermectin as a repurposed anti-cancer agent.

Bikman explained that ivermectin blocks NF-κB from translocating into the nucleus, preventing it from driving the production of pro-inflammatory cytokines. In animal models, ivermectin reduced inflammatory markers after a lethal dose of lipopolysaccharide (LPS) — a bacterial component that triggers sepsis-like inflammation — and significantly increased survival. In models of allergic asthma, therapeutic doses reduced immune cell recruitment into the airway, lowered circulating cytokine levels, and suppressed immunoglobulin E, a key mediator of allergic response. He tied this back to the mitochondrial mechanism: AMPK activation also suppresses NF-κB, meaning the anti-inflammatory, anti-cancer, and metabolic benefits may stem from a single coherent cascade initiated by complex I inhibition.

Bikman reported that Tennessee, Arkansas, Idaho, Louisiana, and Texas have passed laws allowing pharmaceutical-grade ivermectin to be sold over the counter at pharmacies. He noted this makes obtaining it as straightforward as buying ibuprofen. More states have legislation pending, which could broaden access further. He used this fact to counter the ‘horse dewormer’ narrative, arguing that state legislatures are acknowledging the drug’s safety for human use. He emphasized that OTC status does not remove the need for medical supervision, but it does reflect a favorable risk-benefit ratio recognized at the policy level. Combined with the WHO’s essential medicines listing, he sees this as further evidence that ivermectin’s reputation should be guided by evidence, not political alignment.

Bikman closed the lecture by emphasizing that the political firestorm may be blocking the rigorous clinical trials needed to test ivermectin’s metabolic and anti-cancer potential. He finds this troubling because the drug’s mechanistic rationale and safety history justify serious investigation, not dismissal. He invoked the history of drug repurposing to argue that ivermectin should be studied with the same open-mindedness that allowed metformin to go from a herbal remedy to a cornerstone of diabetes care. He lamented that when a compound has this much signal in preclinical models across multiple disease categories, the appropriate scientific response is to study it more rigorously in humans, not to mock it.